Long-term outcomes in hepatitis B: the REVEAL-HBV study.
about
Reasons why West Africa continues to be a hotbed for hepatocellular carcinomaRisk Factors for the Development of Hepatocellular Carcinoma in ThailandHepatocellular carcinoma: Epidemiology, risk factors and pathogenesisThe global epidemiology of hepatocellular carcinoma: present and futureRecent advances in micro/nanotechnologies for global control of hepatitis B infectionAssessment of hepatic fibrosis regression by transient elastography in patients with chronic hepatitis B treated with oral antiviral agentsChronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels.Hepatitis B Virus Infection during Pregnancy: Transmission and Prevention.Use of RNA interference to modulate liver adenoma development in a murine model transgenic for hepatitis B virus.Tenascin-C expression is associated with poor prognosis in hepatocellular carcinoma (HCC) patients and the inflammatory cytokine TNF-α-induced TNC expression promotes migration in HCC cells.Is it more cost-effective for patients with chronic hepatitis b to have a trial of interferon before considering Nucleos(t)ide analogue therapy?A major shift of viral and nutritional risk factors affects the hepatocellular carcinoma risk among Ivorian patients: a preliminary report.Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patientsOverrepresentation of IL-10-Expressing B Cells Suppresses Cytotoxic CD4+ T Cell Activity in HBV-Induced Hepatocellular CarcinomaHepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients.Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study.The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to AdefovirAssessment of liver fibrosis by transient elastography in patients with HIV and hepatitis B virus coinfection in Nigeria.Hepatitis B management in vulnerable populations: gaps in disease monitoring and opportunities for improved care.Hepatitis B therapies and antiviral resistance detection and management.Natural history of chronic hepatitis B REVEALed.A review of chronic hepatitis B epidemiology and management issues in selected countries in the Middle East.Natural history of chronic hepatitis B: what exactly has REVEAL revealed?Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis.Chronic hepatitis B virus in young adults: the need for new approaches to management.Seroprevalence of Hepatitis B and Delta viruses among HIV infected population attending Antiretroviral clinic in selected health facilities in Abuja Nigeria.In Vitro Studies Show that Sequence Variability Contributes to Marked Variation in Hepatitis B Virus Replication, Protein Expression, and Function Observed across GenotypesSerum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression.HBV-specific CD4+ cytotoxic T cells in hepatocellular carcinoma are less cytolytic toward tumor cells and suppress CD8+ T cell-mediated antitumor immunity.Week 4 viral load predicts long-term suppression of hepatitis B virus DNA during antiviral therapy: improving hepatitis B treatment in the real world.HIV/HBV co-infection is a significant risk factor for liver fibrosis in Tanzanian HIV-infected adults.Care delivery and outcomes among US veterans with hepatitis B: A national cohort study.A tumour-promoting role of Th9 cells in hepatocellular carcinoma through CCL20 and STAT3 pathways.The effect of long-term entecavir therapy on liver histopathology in patients with chronic viral hepatitis B.Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis.Molecular epidemiology of HBV infection in chronic hepatitis B virus infected patients in northeast India.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.Clinical course of chronic hepatitis B (CHB) presented with normal ALT in Asian American patients.Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: External Validation of a Scoring System.
P2860
Q26772209-16FB2C9E-536A-4CA9-B5FC-B4EDE3FF8EC7Q26775650-067DE3E1-ACB7-476B-9455-B9E5A0AC28FAQ27489394-3E09AC20-DE33-4FFA-9E60-576D19A868C5Q28654353-9A8C69DB-260E-46AC-9A3D-8F6E06F3021EQ30394611-67ABFC65-E191-425C-870F-877E137B2D87Q30439873-F12B6DBD-A2B3-41DC-852A-B330EC945937Q33718958-1D51C1C5-0572-482E-9C19-8A707C5F67EDQ34084987-ED515FD1-B31F-4BB2-A8DD-42843D10AF7FQ34135030-7E2A9CF1-DA31-49B3-826A-930B24268108Q34184400-63AFADA5-A7C7-48AA-9384-10C3B57F0871Q34669811-CB769D33-2D1D-486F-847A-CEEC93D7FE98Q35118955-C0B37F1E-F501-4754-91D5-FE75969447ACQ35800572-BD3BCA21-703B-4298-9162-FF255591AD62Q35833258-EECCD61E-64C9-48B3-9154-A2CC6F8D7700Q36005233-E087DB4E-E6D2-4886-8478-436034658504Q36695222-6BBB737C-8B42-4244-93ED-88706CE702BAQ36764962-50B68426-2DC4-4540-82A1-2295780F4170Q36805368-D1162449-E1B2-4FCD-B10C-C8DFCBC93F47Q37342624-3D03B385-2F15-48C7-9320-4C0BB6D63338Q37625950-096565F6-2993-4B9C-A305-9F1262C7584EQ37636111-2471458E-FD09-44DC-805B-4BC76FE03242Q37842664-AD083B9C-2A44-4788-9978-FB8CC09D5317Q37970382-27CCDA9A-CD04-4645-93BF-0B86CC658101Q38003214-84CBB935-9C39-46DF-BE14-978D7ACDF681Q38096069-D9384037-A300-477F-B4E0-7478159EB150Q38232829-6686AE5D-3927-4929-8357-A094AA0F0B45Q38602272-6AC81B2F-1E47-4537-BB09-3A78DF980B3AQ38736225-EE09A8CE-DD23-4F78-B3F0-D0F2D1248EA0Q38881102-2FA41693-CF8A-45CD-B1EF-B8A76DE5E1D4Q39244731-A13F7553-F63A-4A33-B48E-A5274072692BQ39443390-5C9FE5E9-DAA7-4988-A835-85FEFCD2779FQ40145541-7299387F-22BE-4E75-8D5A-4336730C2E50Q40329784-686F17E0-EBB5-4A56-B3C0-26CD6A8BCE77Q40503744-A7B5AF34-7B2C-4602-9262-389E47BA271FQ40715967-94C74B03-F39F-4013-99C1-E4520CF17528Q40780258-F7BF1B09-A1B2-46C2-AB2A-ED197CB86C3FQ41005104-BDBFF6F5-5E07-4793-B2EB-2D876049187FQ41962614-CE744288-EC8D-41DB-ADC4-B15FED730CB4Q42174357-894EAB76-BCFC-48C5-A18F-760E92F88420Q42180497-F6FCA611-DEE5-4160-B51B-31140E0B2239
P2860
Long-term outcomes in hepatitis B: the REVEAL-HBV study.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Long-term outcomes in hepatitis B: the REVEAL-HBV study.
@en
type
label
Long-term outcomes in hepatitis B: the REVEAL-HBV study.
@en
prefLabel
Long-term outcomes in hepatitis B: the REVEAL-HBV study.
@en
P2093
P1476
Long-term outcomes in hepatitis B: the REVEAL-HBV study.
@en
P2093
Chien-Jen Chen
Hwai-I Yang
Uchenna H Iloeje
P304
797-816, viii
P356
10.1016/J.CLD.2007.08.005
P577
2007-11-01T00:00:00Z